Issue: July 2024
Fact checked byShenaz Bagha

Read more

June 12, 2024
2 min read
Save

‘Very important’: Belimumab decreases lupus flare vs. placebo in early, established disease

Issue: July 2024
Fact checked byShenaz Bagha
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Treatment with belimumab resulted in fewer flares in patients with either early or established systemic lupus erythematosus, especially among those with no baseline organ damage, according to data presented at the EULAR 2024 Congress.

“The benefits of early treatment of SLE for the prevention of repeated flares of disease activity, as well as the need to limit glucocorticoid exposure, are increasingly recognized,” study co-author Karen Costenbader, MD, MPH, professor of medicine at Harvard Medical School and lupus program director at Brigham and Women’s Hospital, told Healio. “The 2023 EULAR guidelines for the treatment of SLE recommend earlier use of biologics at the same time as other immunosuppressants are considered.

Ace the Case: A 37-Year-Old African American Woman With Lupus Nephritis
“This is very important information for clinicians, as preventing flares is a central goal of treating lupus,” Karen Costenbader, MD, MPH, told Healio. Image: Adobe Stock
Karen Costenbader

“Thus, we examined data from the pooled analyses of belimumab from all registrational clinical trials to investigate flare rates and prevention of flares among those treated earlier vs. later in their disease course,” she added.

To examine SLE flares in patients with either early or established disease who have received belimumab (Benlysta, GlaxoSmithKline), alongside standard therapy, Costenbader and colleagues conducted a post hoc analysis that pooled data from five international phase 3 trials. The included trials were BLISS-76, BLISS-52, North East Asia, EMBRACE and BLISS-SC. Adults with SLE were randomly assigned to receive either belimumab (n = 1,869) or placebo (n = 1,217). Both groups additionally received standard therapy.

The researchers assessed time to lupus flare across 52 weeks in subgroups of early vs. established disease. Meanwhile, lupus flares were assessed based on definitions from the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index flare index (SFI) and the British Isles Lupus Assessment Group (BILAG).

Over 52 weeks, a significantly fewer number of patients treated with belimumab demonstrated a severe SFI flare (HR = 0.61; 95% CI, 0.51-0.72), any SFI flare (HR = 0.83; 95% CI, 0.76-0.91) or any BILAG flare (HR = 0.72; 95% CI, 0.62-0.83) vs. placebo, according to the researchers.

Patients treated with belimumab also had fewer flares in both subgroups of early and established disease. Patients with early disease demonstrated fewer flares whether treated with belimumab or placebo.

“This post hoc analysis showed fewer patients experienced flares with belimumab versus placebo in the pooled population and in early or established disease subgroups, with particular benefit suggested in patients with no baseline organ damage,” Costenbader said. “The proportion of patients with flares was lower in those with early versus established disease, for belimumab and placebo.

“This is very important information for clinicians as preventing flares is a central goal of treating lupus,” she added. “Every time there is a flare, more organ damage occurs, as does more exposure to glucocorticoids. These results were not included in the original trial reports.”